Want to see CH:IDIA full AI Analyst Report?
IDIA Stock Chart & Stats
CHF3.71
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF3.71
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF2.42 - CHF7.56
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF1.60B
Enterprise ValueCHF2.12K
Total Cash (Recent Filing)CHF94.70M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Jul 30, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding263,059,780
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.67Price Target Upside25.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.54
Revenue Forecast (FY)CHF221.54M
Bulls Say, Bears Say
Bulls Say
High Product-level Gross MarginsSustained ~90% gross margins indicate strong product economics and pricing power at the unit level. Over months this supports durability of incremental revenue conversion to gross profit, enabling margin recovery if operating costs are controlled or scaled across a larger revenue base.
Diversified Revenue Model (sales + Licensing)A dual revenue model combining direct product sales and licensing/partnership income smooths cash flow sources and de-risks commercialization. Durable partnership payments, milestones and royalties can offset product uptake timing and provide multiple avenues for value realization over 2–6 months and beyond.
Proven Ability To Scale Commercial RevenueA history of growing commercial sales demonstrates the company can build distribution, reimbursement and prescriber traction. That commercial capability is lasting: a functioning sales and regulatory footprint increases the odds new launches or geography expansion translate into sustained revenues.
Bears Say
Stressed Balance Sheet And LeverageDeeply negative equity and debt materially weaken financial flexibility and raise refinancing risk. Over a multi-month horizon this constrains investment, increases funding costs, and limits ability to withstand setbacks in development or commercial rollouts without dilutive or expensive capital solutions.
Persistent Negative Cash GenerationSustained negative OCF and FCF indicate the business consumes cash to operate. Absent material near-term milestone receipts or cost cuts, ongoing cash burn will pressure liquidity and force financing, which is a structural headwind to reinvesting in R&D or commercial expansion over the coming months.
Operating Losses And Revenue VolatilitySharp recent revenue decline alongside heavy operating losses shows earnings are unstable and cost base is not elastic. This structural volatility makes forecasting cash needs and achieving sustainable profitability difficult without clear, durable revenue recovery or meaningful operating leverage.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF2.42 and its highest was CHF7.56 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.60B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Apr 28, 2026. The company reported -CHF0.14 earnings per share for the quarter, beating the consensus estimate of -CHF0.185 by CHF0.045.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.2.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 263,059,780 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.14 in its last earnings report, beating expectations of -CHF0.185. Following the earnings report the stock price went up 4.782%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.67
▲(25.79% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―